Willow Biosciences Inc.
WLLW.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.38M | 2.10M | 1.36M | 706.20K | 871.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.38M | 2.10M | 1.36M | 706.20K | 871.00K |
| Cost of Revenue | 1.00M | 3.63M | 3.78M | 4.32M | 5.04M |
| Gross Profit | 3.72M | -1.53M | -2.42M | -3.61M | -4.17M |
| SG&A Expenses | 2.78M | 3.09M | 2.92M | 3.32M | 4.48M |
| Depreciation & Amortization | 1.01M | 1.03M | 1.21M | 1.28M | 1.36M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.48M | 7.74M | 7.91M | 8.92M | 10.88M |
| Operating Income | -4.10M | -5.64M | -6.56M | -8.22M | -10.01M |
| Income Before Tax | -4.53M | -5.43M | -6.30M | -7.88M | -9.66M |
| Income Tax Expenses | 8.50K | 243.00K | 122.00K | -2.00K | -3.50K |
| Earnings from Continuing Operations | -4.54 | -5.68 | -6.43 | -7.88 | -9.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.54M | -5.68M | -6.43M | -7.88M | -9.65M |
| EBIT | -4.10M | -5.64M | -6.56M | -8.22M | -10.01M |
| EBITDA | -3.47M | -5.13M | -6.00M | -7.64M | -9.37M |
| EPS Basic | -0.03 | -0.04 | -0.05 | -0.06 | -0.08 |
| Normalized Basic EPS | -0.02 | -0.03 | -0.03 | -0.04 | -0.05 |
| EPS Diluted | -0.03 | -0.04 | -0.05 | -0.06 | -0.08 |
| Normalized Diluted EPS | -0.02 | -0.03 | -0.03 | -0.04 | -0.05 |
| Average Basic Shares Outstanding | 536.16M | 518.12M | 501.23M | 498.15M | 496.43M |
| Average Diluted Shares Outstanding | 536.16M | 518.12M | 501.23M | 498.15M | 496.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |